TrivarX Limited (ASX: TRI) announced a binding option to acquire Stabl-Im™, a stable-isotope MRI platform intended to enable early, repeatable, non-invasive detection and monitoring of brain tumours and metastases—an area with high unmet clinical need and limited safe imaging options. The transaction is paired with a $4.2m placement cornerstoned by Dr Daniel Tillett (founder/CEO of Nucleics and MD/CEO of Race Oncology, ASX: RAC), signalling both technical belief and strategic

Race Oncology Limited (ASX: RAC) has reported a pivotal mechanistic discovery: its lead molecule (E,E)-bisantrene (RCDS1) primarily exerts anticancer activity by binding and stabilising G-quadruplex (G4) structures in DNA and RNA—not via an anthracycline-like pathway. The company positions this as a step-change for clinical strategy, biomarker development, and partnering.

Echo IQ Limited (ASX: EIQ) has delivered a concise update showing rising clinical usage for EchoSolv™ AS, clear progress on EchoSolv™ HF’s FDA pathway, and expanding commercial channels in the US and Europe. The near-term catalysts are anchored in actual hospital integrations, validation work nearing completion, and newly appointed US key opinion leaders guiding adoption.

The Calmer Co. International Limited (ASX: CCO) has reported the strongest quarter in its history with Q1 FY26 sales of $2.4 million, up 26% on Q4 FY25 ($1.9m). Growth was broad-based across Australian retail, the USA, and B2B channels, with additional funding commitments to support inventory and expansion.

Algorae Pharmaceuticals Ltd (ASX: 1AI) has taken a major step toward establishing a commercial presence in the Australian and New Zealand markets. The company has entered into an exclusive licensing agreement with global pharmaceutical manufacturer Sakar Healthcare Limited (NSE: SAKAR, BSE: 538377) (Figure 1) to launch five oncology medicines across the region.

When Race Oncology Limited’s (ASX: RAC) share price doubled at the start of last week, many investors were left asking the same question – what just happened? The answer, as is often the case with biotech catalysts, lies in a combination of significant scientific developments, strong IP positioning, and a clear signal to the market that management is preparing for the next stage of value creation.

On 25 July 2025, Opyl Limited (ASX: OPL) officially rebranded to Pathkey.AI (ASX: PKY) – a move signalling a sharpened focus on applying artificial intelligence to the most critical challenges in clinical trials and drug development. Rather than being “just another med-tech rebrand,” Pathkey.AI represents a company building a sophisticated decision-support ecosystem designed to help therapies get to patients faster, de-risk trials for sponsors, and improve capital efficiency

Founded in Christchurch, New Zealand, in 1984, Ryman Healthcare (NZX: RYM) has grown into one of Australasia’s leading operators of retirement villages and aged care services (Figure 1). For over forty years, the company’s guiding principle has been simple yet powerful — that everything it does must be “good enough for mum and dad.” This philosophy has shaped Ryman’s reputation as a trusted brand, built around its purpose of enhancing freedom, connection, and well-being for o

Race Oncology Limited (ASX: RAC) has announced a major scientific breakthrough that could reshape its commercial and clinical trajectory. The company has discovered that bisantrene – a clinically validated cancer drug – exists as three photoisomers, with only the (E,E)-bisantrene form possessing significant anticancer activity. This discovery has enabled Race to file three new patent applications, potentially providing composition of matter intellectual property (IP) protecti

Proteomics International Laboratories Ltd (ASX: PIQ) has been granted ISO 15189 certification for its Australian laboratory operations – a key milestone that cements its role as a leader in precision diagnostics. This certification validates the company’s systems, processes, and quality management, ensuring accurate and dependable clinical results.

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) has highlighted the successful commercial launch of its flagship therapy, Ryoncil® (remestemcel-L-rknd), at two major global healthcare conferences — Morgan Stanley and Cantor Fitzgerald’s Annual Global Healthcare events in New York. This milestone underscores Mesoblast’s position as a global leader in allogeneic cellular medicines for inflammatory diseases.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has presented important data from its ATH434-201 Phase 2 clinical trial at the 150th Annual Meeting of the American Neurological Association (ANA) in Baltimore, USA. The trial focused on Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease. These results mark a significant milestone for Alterity as it moves closer to providing the first disease-modifying therapy for MSA.

Proteomics International Laboratories (ASX: PIQ) has unveiled new results for its PromarkerEso blood test, a patented, first-in-class diagnostic that delivers a simple and scalable pathway for early detection. With clinical validation showing high accuracy in identifying early-stage EAC, PromarkerEso may well change the standard of care in managing this difficult disease. With patents already granted in Europe, China, and Australia—and other territories pending.

Actinogen Medical Limited (ASX: ACW) has announced a significant milestone in the development of Xanamem®, its lead therapy for Alzheimer’s disease (AD). Following a successful Type C meeting with the US Food and Drug Administration (FDA), the Company now has clear guidance on the remaining clinical, manufacturing, and regulatory requirements for a New Drug Application (NDA) submission in the US.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on disease-modifying treatments for neurodegenerative diseases, has successfully raised A$20.0 million through a strategic placement to international and Australian professional investors.